TERN — Terns Pharmaceuticals Cashflow Statement
0.000.00%
Last trade - 00:00- $4.78bn
- $4.48bn
- 49
- 21
- 99
- 57
Annual cashflow statement for Terns Pharmaceuticals, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -40.6 | -50.2 | -60.3 | -90.2 | -88.9 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 4.62 | 9.03 | 11.4 | 21.1 | 14.1 |
| Other Non-Cash Items | |||||
| Changes in Working Capital | 5.06 | -1.43 | -1.04 | 1.29 | 4.38 |
| Change in Prepaid Expenses | |||||
| Change in Other Assets | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Other Liabilities | |||||
| Cash from Operating Activities | -29.8 | -41.8 | -49.1 | -67.4 | -70 |
| Capital Expenditures | -0.584 | -0.34 | -0.275 | -0.052 | -0.042 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 7.28 | -119 | -22 | -37.9 | -12.4 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 6.69 | -120 | -22.3 | -38 | -12.4 |
| Financing Cash Flow Items | -0.858 | -2.72 | -0.401 | -0.344 | -0.388 |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 85.5 | 134 | 167 | 42 | 164 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 62.5 | -27.2 | 95.5 | -63.3 | 81.5 |